Skip to main content
Evidence Snapshot

Tyrosine-protein kinase receptor UFO

CHEMBL4895 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:25Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4895
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase receptor UFO as ChEMBL target CHEMBL4895, mapped to UniProt P30530. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase receptor UFO
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4895
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P30530
Tyrosine-protein kinase receptor UFO
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tyrosine-protein kinase receptor UFO matters

As of 2026-09-14

Tyrosine-protein kinase receptor UFO is reviewed as Tyrosine-protein kinase receptor UFO (UniProt P30530); Tyrosine-protein kinase receptor UFO shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 25 approved drugs, 5070 compounds, and 646 assays, with lead potency reaching pChEMBL 11.0.

Disease context
neoplasm

Tyrosine-protein kinase receptor UFO shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BEMCENTINIB, BPI-9016, GILTERITINIB.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BEMCENTINIB, BPI-9016, GILTERITINIB, MECBOTAMAB VEDOTIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 25 approved drugs, 5070 compounds, and 646 assays for this target. The dominant activity type is IC50. CHEMBL5758853 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL5758853 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
25 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tyrosine-protein kinase receptor UFO matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30530, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5070
Total Compounds
646
Total Assays
25
Approved Drugs
IC50: 3869.0, KI: 883.0, EC50: 39.0, KD: 143.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5758853
 11.0 Ki —
No preferred name
CHEMBL5932919
 10.9 Ki —
No preferred name
CHEMBL5935453
 10.9 Ki —
No preferred name
CHEMBL5792035
 10.8 Ki —
No preferred name
CHEMBL5923596
 10.8 Ki —

Approved Drugs

Structure Compound First Approval
ENTRECTINIB
CHEMBL1983268
 2019
FEDRATINIB
CHEMBL1287853
 2019
GILTERITINIB
CHEMBL3301622
 2018
NERATINIB
CHEMBL180022
 2017
MIDOSTAURIN
CHEMBL608533
 2017
NINTEDANIB
CHEMBL502835
 2014
CABOZANTINIB
CHEMBL2105717
 2012
BOSUTINIB
CHEMBL288441
 2012
AXITINIB
CHEMBL1289926
 2012
CRIZOTINIB
CHEMBL601719
 2011
VANDETANIB
CHEMBL24828
 2011
SUNITINIB
CHEMBL535
 2006
SORAFENIB
CHEMBL1336
 2005
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:25Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4895